# Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

> **NCT01515748** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 530 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel (XRP6976)
- **DRUG:** Oxaliplatin (SR96669)
- **DRUG:** S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)

## Key facts

- **NCT ID:** NCT01515748
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-30
- **Primary completion:** 2019-01-21
- **Final completion:** 2021-12-13
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515748, "Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01515748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*